Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentPhase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisOptimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Current and future management of Ph/BCR-ABL positive ALL.An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.[Tailored management of chronic myeloid leukemia].Chronische myeloische Leukämie
P2860
Q26766299-B2CC3960-7E08-4D42-A126-99D3CB188FE6Q33402841-FA0BF5CB-85FC-4F37-AF54-C1B92AFA4E00Q35953410-713D145C-66A9-4FFA-9748-97982B81FE7FQ37026032-F2F8DC7E-EF1A-4CE6-A349-EDE7BAE8FE01Q37102026-709C444F-5B3E-4B12-B404-10DB1518B169Q37212678-FC11C543-51D2-448F-B981-B637EBE9D137Q38023947-2C320434-896F-46B1-B1A9-A0516191E0D3Q38057413-D96552A1-4BCB-4120-A528-E7ACF2D5F212Q38087930-0CB41A8C-C0BB-4892-90C3-DE42457736DAQ38194585-07E06C41-A9DD-4722-9E3F-8C99D76CCB1BQ38236642-31A6678F-C7B5-42C7-A3E2-0A73C8F01B81Q38767908-7DABDA60-D435-4FF2-A1F0-7FF9E82789E3Q41539993-0917954D-F15D-4403-84FD-DF9A1B03A0BDQ43572027-D019FC47-9E64-43EE-958C-399C82B7D0A6Q54398375-BF3546CC-C6CE-4B89-A59B-90087839938FQ58023770-F455CEC8-787B-483F-B8A9-7396A7F2A837
P2860
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@en
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@nl
type
label
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@en
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@nl
prefLabel
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@en
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@nl
P2093
P2860
P50
P1433
P1476
Allogeneic stem cell transplan ...... 15I BCR-ABL mutated leukemias.
@en
P2093
Charles Chuah
Eduardo Olavarria
Franck Emmanuel Nicolini
Gabriel Etienne
Giovanna Rege-Cambrin
Grzegorz W Basak
Hélène Labussière
Inge H Dufva
Jane F Apperley
Martin C Müller
P2860
P304
P356
10.1182/BLOOD-2011-07-367326
P407
P577
2011-09-16T00:00:00Z